Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer

Clinical Cancer Research

Volumn 20, Issue 12, 2014, Pages 3159-3173

  Chittaranjan, Suganthi ^a   Bortnik, Svetlana ^a   Dragowska, Wieslawa H ^a   Xu, Jing ^a,b   Abeysundara, Namal ^a   Leung, Amy ^a   Go, Nancy E ^a,b   DeVorkin, Lindsay ^a,b   Weppler, Sherry A ^a   Gelmon, Karen ^a   Yapp, Donald T ^a   Bally, Marcel B ^a   Gorski, Sharon M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AUTOPHAGY PROTEIN 5; AUTOPHAGY PROTEIN 7; CELL PROTEIN; DOXORUBICIN; EPIRUBICIN; HYDROXYCHLOROQUINE; MITOXANTRONE; UNCLASSIFIED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; HUMAN; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; HUMANS; MICE; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902652254     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2060     Document Type: Article

References (47)

1. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-60. (Pubitemid 46202348)
2. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011;16(Suppl 1):1-11.
3. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
4. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-9.
5. Amaravadi RK, Lippincott-Schwartz J, Yin X-M, Weiss WA, Takebe N, Timmer W, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011;17:654-66.
6. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42.
7. Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. Nat Cell Biol 2007;9:1102-9. (Pubitemid 47500484)
8. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 2005;12(Suppl 2):1509-18. (Pubitemid 41553987)
9. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005;6:439-48. (Pubitemid 40780556)
10. Mortimore GE, Schworer CM. Induction of autophagy by amino-acid deprivation in perfused rat liver. Nature 1977;270:174-6. (Pubitemid 8209074)
11. Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008;68:1485-94. (Pubitemid 351346857)
12. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, et al. Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Treat 2008;112:389-403.
13. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 2007;26:1749-60. (Pubitemid 46624042)
14. Shen S, Kepp O, Michaud M, Martins I, Minoux H, Métivier D, et al. Association and dissociation of autophagy, apoptosis and necrosis by systematic chemical study. Oncogene 2011;30:4544-56.
15. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res 2009;15:5308-16.
16. Gewirtz DA. Autophagy as a mechanism of radiation sensitization in breast tumor cells. Autophagy 2007;3:249-50. (Pubitemid 46752688)
17. Samaddar JS, Gaddy VT, Duplantier J, Thandavan SP, Shah M, Smith MJ, et al. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther 2008;7:2977-87.
18. Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 2007;14:500-10.
19. Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, et al. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther 2012;11:973-83.
20. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007;117:326-36. (Pubitemid 46203961)
21. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119:1109-23.
22. Armstrong LJ, Gorski SM. Breast cancer and autophagy. In:Romero ME, Dashek LM, editors. In breast cancer: causes, diagnosis and treatment. New York: Nova Science Publishers Inc.; 2010. p. 53-88.
23. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010;140:313-26.
24. Chen N, Karantza V. Autophagy as a therapeutic target in cancer. Cancer Biol Ther 2011;11:157-68.
25. Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene 2010;29:6085-98.
26. John S, Nayvelt I, Hsu H-C, Yang P, Liu W, Das GM, et al. Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Res 2008;68:7855-63.
27. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012;8:445-544.
28. Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 2007;3:452-60. (Pubitemid 47293726)
29. Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 2003;4(Suppl 1):S26-33. (Pubitemid 36621613)
30. Sun W-L, Chen J, Wang Y-P, Zheng H. Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 2011;7:1035-44.
31. Beretta G, Locatelli C, Tabiadon D, Labianca R, Fraschini P, Luporini G. Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen. Oncology 1987;44:6-12. (Pubitemid 17028384)
32. Hunz M, Jetter A, Warm M, Pantke E, Tuscher M, Hempel G, et al. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Clin Pharmacol Ther 2007;81:659-68. (Pubitemid 46625101)
33. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research CDER. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers [Internet]. 2005 [cited 2013 May 27]. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf.
34. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS ONE 2009;4:e6251.
35. Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 2010;1806:220-9.
36. Choi J, Jung W, Koo JS. Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Histopathology 2013;62:275-86.
37. Zhao H, Yang M, Zhao J, Wang J, Zhang Y, Zhang Q. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer. Med Oncol 2013;30:475.
38. Thomas S, Sharma N, Golden EB, Cho H, Agarwal P, Gaffney KJ, et al. Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett 2012;325:63-71.
39. Amaral C, Borges M, Melo S, da Silva ET, Correia-da-Silva G, Teixeira N. Apoptosis and autophagy in breast cancer cells following exemestane treatment. PLoS ONE 2012;7:e42398.
40. Oh S-H, Lim S-C. Endoplasmic reticulum stress-mediated autophagy/apoptosis induced by capsaicin (8-methyl-N-vanillyl-6-nonenamide) and dihydrocapsaicin is regulated by the extent of c-Jun NH2-terminal kinase/extracellular signal-regulated kinase activation in WI38 lung epithelial fibroblast cells. J Pharmacol Exp Ther 2009;329:112-22.
41. Kimmelman AC. The dynamic nature of autophagy in cancer. Genes Dev 2011;25:1999-2010.
42. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM, et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 2011;22:165-78.
43. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomasand maintains lipid homeostasis. Genes Dev 2013;27:1447-61.
44. Guo JY, Chen H-Y, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011;25:460-70.
45. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993;23:82-91.
46. +-ATPase impair the preferential accumulation of daunomycin in lysosomes and reverse the resistance to anthracyclines in drug-resistant renal epithelial cells. Biochem J 2003;370:185-93.
47. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma X-H, Piao S, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci U S A. 2012;109:8253-8.